|
|
Advances in Engineered Mesenchymal Stem Cells in Tumor Therapy |
WANG Qin-yao1,2,WANG Xi-xi1,2,LI Li2,HU Yao-sheng2,SA Ya-lian2,**() |
1 Medical School, Kunming University of Science and Technology, Kunming 650500, China 2 Center for Clinical Medicine Research(Yunnan Provincial Key Laboratory of Clinical Virology), The First People’s Hospital of Yunnan Province (Affiliated Hospital of Kunming University of Science and Technology), Kunming 650032, China |
|
|
Abstract Mesenchymal stem cells (MSCs) are adult multipotent stem cells possessing the advantages of rich and wide sources, low immunogenicity, homing to the tissue of injury, paracrine activity, immunomodulation capacity, and easiness to be engineered. With the above-mentioned advantages, MSCs may have great application value in the treatment of cancer. Despite the controversial roles of MSC in cancer therapy, engineering MSCs with homing capacity to tumor tissues show great antitumor potential for delivering anticancer agents, suicide genes, and oncolytic viruses to tumors. Current clinical trial utilizing engineered MSCs in GBM treatment was shown to exert anti-GBM activity. Therefore, the following review elaborates on the characteristics of MSCs as well as the effects of engineering MSCs on tumor cells and their microenvironments, in order to provide new insights into MSCs’ value in translational medicine and tumor treatment.
|
Received: 04 April 2023
Published: 01 December 2023
|
|
Corresponding Authors:
**Ya-lian SA
E-mail: sayalian@126.com
|
|
|
[1] |
Weinberg R A. The biology of cancer. 2nd ed., Taylor & Francis Group, LLC, 2013.
|
|
|
[2] |
Tsimberidou A M, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86: 102019.
doi: 10.1016/j.ctrv.2020.102019
|
|
|
[3] |
Ding D C, Shyu W C, Lin S Z. Mesenchymal stem cells. Cell Transplantation, 2011, 20(1): 5-14.
doi: 10.3727/096368910X
|
|
|
[4] |
Giselle C, James F, Brian A, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells (Dayton, Ohio), 2007, 25(11): 2739-2749.
doi: 10.1634/stemcells.2007-0197
|
|
|
[5] |
李士欣, 华映坤, 王林坪, 等. 人脐带Wharton’s jelly间充质干细胞生物学特性的研究. 中国临床解剖学杂志, 2014, 32(4): 432-436.
|
|
|
[5] |
Li S X, Hua Y K, Wang L P, et al. Study on biological characterization of Wharton’s jelly mesenchymal stem cells from human umbilical cord. Chinese Journal of Clinical Anatomy, 2014, 32(4): 432-436.
|
|
|
[6] |
撒亚莲, 沈晓梅, 史克倩, 等. hMSC对异体DC-CIK细胞分泌细胞因子的影响. 细胞与分子免疫学杂志, 2010, 26(10): 988-991.
|
|
|
[6] |
Sa Y L, Shen X M, Shi K Q, et al. Effects of human bone marrow mesenchymal stem cells on cytokines secretion from allogeneic dendritic cell activated cytokine-induced killer cells. Chinese Journal of Cellular and Molecular Immunology, 2010, 26(10):988-991.
|
|
|
[7] |
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006, 8(4): 315-317.
doi: 10.1080/14653240600855905
pmid: 16923606
|
|
|
[8] |
Lanza R P, Atala A. Essentials of stem cell biology. 2nd ed. Amsterdam, the Netherlands: Elsevier/Academic Press, 2014.
|
|
|
[9] |
Farkhad N K, Mahmoudi A, Mahdipour E. How similar are human mesenchymal stem cells derived from different origins? A review of comparative studies. Current Stem Cell Research & Therapy, 2021, 16(8): 980-993.
|
|
|
[10] |
Ullah I, Subbarao R, Rho G. Human mesenchymal stem cells - current trends and future prospective. Bioscience Reports, 2015, 35(2): BSR20150025.
|
|
|
[11] |
Ankrum J A, Ong J F, Karp J M. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology, 2014, 32(3): 252-260.
doi: 10.1038/nbt.2816
pmid: 24561556
|
|
|
[12] |
Sun Z, Wang S H, Zhao R C. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. Journal of Hematology & Oncology, 2014, 7(1): 1-10.
|
|
|
[13] |
Kalluri R, LeBleu V S. The biology,function,and biomedical applications of exosomes. Science, 2020, 367(6478): eaau6977.
doi: 10.1126/science.aau6977
|
|
|
[14] |
Brennan M Á, Layrolle P, Mooney D J. Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration. Advanced Functional Materials, 2020, 30(37): 1909125.
doi: 10.1002/adfm.v30.37
|
|
|
[15] |
Lepelletier Y, Lecourt S, Renand A, et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells and Development, 2010, 19(7): 1075-1079.
doi: 10.1089/scd.2009.0212
pmid: 19886821
|
|
|
[16] |
Cheung T S, Bertolino G M, Giacomini C, et al. Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers. Frontiers in Immunology, 2020, 11: 1338.
doi: 10.3389/fimmu.2020.01338
pmid: 32670295
|
|
|
[17] |
Heidari N, Abbasi-Kenarsari H, Namaki S, et al. Adipose-derived mesenchymal stem cell-secreted exosome alleviates dextran sulfate sodium-induced acute colitis by Treg cell induction and inflammatory cytokine reduction. Journal of Cellular Physiology, 2021, 236(8): 5906-5920.
doi: 10.1002/jcp.30275
pmid: 33728664
|
|
|
[18] |
Harrell C R, Jovicic N, Djonov V, et al. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells, 2019, 8(12): 1605.
doi: 10.3390/cells8121605
|
|
|
[19] |
Zhao L, Chen S Q, Yang P X, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Research & Therapy, 2019, 10(1): 182.
|
|
|
[20] |
Wang X N, Zhang M, He P. Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. J Int Med Res, 2020, 48: 300060520920438.
|
|
|
[21] |
Boberg E, Bahr L, Afram G, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Translational Medicine, 2020, 9(10): 1190-1202.
doi: 10.1002/sctm.20-0099
|
|
|
[22] |
Soder R P, Dawn B, Weiss M L, et al. A phase I study to evaluate two doses of Wharton’s jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease. Stem Cell Reviews and Reports, 2020, 16(5): 979-991.
doi: 10.1007/s12015-020-10015-8
|
|
|
[23] |
Goto T, Murata M, Nishida T, et al. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. Stem Cells Translational Medicine, 2021, 10(4): 542-553.
doi: 10.1002/sctm.20-0381
pmid: 33314650
|
|
|
[24] |
Zhao K, Lin R, Fan Z P, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. Journal of Hematology & Oncology, 2022, 15(1): 22.
|
|
|
[25] |
Stenger E, Giver C R, Langston A, et al. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease. Frontiers in Immunology, 2022, 13: 959658.
doi: 10.3389/fimmu.2022.959658
|
|
|
[26] |
Nagamura-Inoue T, Kato S, Najima Y, et al. Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease. International Journal of Hematology, 2022, 116(5): 754-769.
doi: 10.1007/s12185-022-03408-7
|
|
|
[27] |
Petinati N, Davydova Y, Nikiforova K, et al. T cell and cytokine dynamics in the blood of patients after hematopoietic stem cell transplantation and multipotent mesenchymal stromal cell administration. Transplantation and Cellular Therapy, 2023, 29(2): 109.e1-109.e10.
doi: 10.1016/j.jtct.2022.10.030
|
|
|
[28] |
Harrell C R, Volarevic A, Djonov V G, et al. Mesenchymal stem cell: a friend or foe in anti-tumor immunity. International Journal of Molecular Sciences, 2021, 22(22): 12429.
doi: 10.3390/ijms222212429
|
|
|
[29] |
Raj A T, Kheur S, Bhonde R, et al. Assessing the effect of human mesenchymal stem cell-derived conditioned media on human cancer cell lines: a systematic review. Tissue and Cell, 2021, 71: 101505.
doi: 10.1016/j.tice.2021.101505
|
|
|
[30] |
Rubinstein-Achiasaf L, Morein D, Ben-Yaakov H, et al. Persistent inflammatory stimulation drives the conversion of MSCs to inflammatory CAFs that promote pro-metastatic characteristics in breast cancer cells. Cancers, 2021, 13(6): 1472.
doi: 10.3390/cancers13061472
|
|
|
[31] |
Sandiford O A, Donnelly R J, ElFar M H, et al. Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. Cancer Research, 2021, 81(6): 1567-1582.
doi: 10.1158/0008-5472.CAN-20-2434
pmid: 33500249
|
|
|
[32] |
Chen Y C, Gonzalez M E, Burman B, et al. Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer. Cell Reports, 2019, 27(13): 3916-3926.e5.
doi: 10.1016/j.celrep.2019.05.084
|
|
|
[33] |
Zhou X H, Li T, Chen Y F, et al. Mesenchymal stem cell-derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway. International Journal of Oncology, 2019, 54:1843-1852.
|
|
|
[34] |
Wei H J, Nickoloff J A, Chen W H, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget, 2014, 5(19): 9514-9529.
doi: 10.18632/oncotarget.v5i19
|
|
|
[35] |
Luo D, Hu S Y, Tang C L, et al. Mesenchymal stem cells promote cell invasion and migration and autophagy-induced epithelial-mesenchymal transition in A 549 lung adenocarcinoma cells. Cell Biochemistry and Function, 2018, 36(2): 88-94.
doi: 10.1002/cbf.v36.2
|
|
|
[36] |
Miloradovic D, Miloradovic D, Markovic B S, et al. The effects of mesenchymal stem cells on antimelanoma immunity depend on the timing of their administration. Stem Cells International, 2020, 2020: 1-13.
|
|
|
[37] |
Bashyal N, Lee T Y, Chang D Y, et al. Improving the safety of mesenchymal stem cell-based ex vivo therapy using Herpes simplex virus thymidine kinase. Molecules and Cells, 2022, 45(7): 479-494.
doi: 10.14348/molcells.2022.5015
|
|
|
[38] |
Villatoro A J, Alcoholado C, del Carmen Martín-Astorga M, et al. Suicide gene therapy by canine mesenchymal stem cell transduced with thymidine kinase in a u-87 glioblastoma murine model: secretory profile and antitumor activity. PLoS One, 2022, 17(2): e0264001.
doi: 10.1371/journal.pone.0264001
|
|
|
[39] |
Oraee-Yazdani S, Tavanaei R, Rostami F, et al. Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial. J Transl Med, 2023, 21:350.
doi: 10.1186/s12967-023-04213-4
pmid: 37245011
|
|
|
[40] |
Loebinger M R, Eddaoudi A, Davies D, et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Research, 2009, 69(10): 4134-4142.
doi: 10.1158/0008-5472.CAN-08-4698
pmid: 19435900
|
|
|
[41] |
Bae J, Liu L C, Moore C, et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer. Nature Cell Biology, 2022, 24(12): 1754-1765.
doi: 10.1038/s41556-022-01024-5
|
|
|
[42] |
Zhao C Y, Pu Y, Zhang H D, et al. IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis Inhibition. Journal of Cancer, 2020, 11(18): 5345-5352.
doi: 10.7150/jca.38062
pmid: 32742480
|
|
|
[43] |
Zhang H X, Feng Y, Xie X X, et al. Engineered mesenchymal stem cells as a biotherapy platform for targeted photodynamic immunotherapy of breast cancer. Advanced Healthcare Materials, 2022, 11(6): e2101375.
|
|
|
[44] |
Jing W, Chen Y, Lu L, et al. Human umbilical cord blood-derived mesenchymal stem cells producing IL 15 eradicate established pancreatic tumor in syngeneic mice. Molecular Cancer Therapeutics, 2014, 13(8): 2127-2137.
doi: 10.1158/1535-7163.MCT-14-0175
pmid: 24928851
|
|
|
[45] |
Liu X Y, Hu J X, Li Y Y, et al. Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. Oncology Letters, 2018, 15:6265-6274.
doi: 10.3892/ol.2018.8166
pmid: 29725393
|
|
|
[46] |
McGuire J J, Frieling J S, Lo C H, et al. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nature Communications, 2021, 12(1): 1-13.
doi: 10.1038/s41467-020-20314-w
|
|
|
[47] |
Zhang T, Wang Y, Li Q, et al. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity. Oncogene, 2022, 41(13): 1866-1881.
doi: 10.1038/s41388-022-02201-4
pmid: 35145233
|
|
|
[48] |
Park J H, Ryu C H, Kim M J, et al. Combination therapy for gliomas using temozolomide and interferon-beta secreting human bone marrow derived mesenchymal stem cells. Journal of Korean Neurosurgical Society, 2015, 57(5): 323-328.
doi: 10.3340/jkns.2015.57.5.323
|
|
|
[49] |
Yin P, Gui L M, Wang C H, et al. Targeted delivery of CXCL9 and OX40L by mesenchymal stem cells elicits potent antitumor immunity. Molecular Therapy: the Journal of the American Society of Gene Therapy, 2020, 28(12): 2553-2563.
doi: 10.1016/j.ymthe.2020.08.005
|
|
|
[50] |
Ho C T, Wu M H, Chen M J, et al. Combination of mesenchymal stem cell-delivered oncolytic virus with prodrug activation increases efficacy and safety of colorectal cancer therapy. Biomedicines, 2021, 9(5): 548.
doi: 10.3390/biomedicines9050548
|
|
|
[51] |
Yuan X F, Lu Y, Yang Y Y, et al. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma. OncoImmunology, 2023, 12(1): 2219544.
doi: 10.1080/2162402X.2023.2219544
|
|
|
[52] |
Xu L N, Xu M, Sun X, et al. Quantitative comparison of gold nanoparticle delivery via the enhanced permeation and retention (EPR) effect and mesenchymal stem cell (MSC)-based targeting. ACS Nano, 2023, 17(3): 2039-2052.
doi: 10.1021/acsnano.2c07295
|
|
|
[53] |
Xie L X, Zhang C W, Liu M, et al. Nucleus-targeting Manganese dioxide nanoparticles coated with the human umbilical cord mesenchymal stem cell membrane for cancer cell therapy. ACS Applied Materials & Interfaces, 2023, 15(8): 10541-10553.
|
|
|
[54] |
Takayama Y, Kusamori K, Tsukimori C, et al. Anticancer drug-loaded mesenchymal stem cells for targeted cancer therapy. Journal of Controlled Release, 2021, 329: 1090-1101.
doi: 10.1016/j.jconrel.2020.10.037
pmid: 33098911
|
|
|
[55] |
Ho T C, Kim H S, Chen Y M, et al. Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy. Science Advances, 2021, 7(21): eabg3217.
doi: 10.1126/sciadv.abg3217
|
|
|
[56] |
Yun W S, Shim M K, Lim S, et al. Mesenchymal stem cell-mediated deep tumor delivery of gold nanorod for photothermal therapy. Nanomaterials, 2022, 12(19): 3410.
doi: 10.3390/nano12193410
|
|
|
[57] |
Du L, Tao X G, Shen X W.Human umbilical cord mesenchymal stem cell-derived exosomes inhibit migration and invasion of breast cancer cells via miR-21-5p/ZNF367 pathway. Breast Cancer, 2021, 28(4): 829-837.
doi: 10.1007/s12282-021-01218-z
|
|
|
[58] |
Yu T T, Yu H, Xiao D, et al. Human bone marrow mesenchymal stem cell (hBMSCs)-derived miR-29a-3p-containing exosomes impede laryngocarcinoma cell malignant phenotypes by inhibiting PTEN. Stem Cells International, 2022, 2022: 1-14.
|
|
|
[59] |
Bongolo C C, Thokerunga E, Yan Q, et al. Exosomes derived from microRNA-27a-3p overexpressing mesenchymal stem cells inhibit the progression of liver cancer through suppression of Golgi membrane protein 1. Stem Cells International, 2022, 2022: 1-14.
|
|
|
[60] |
Liu P P, Zhang Q, Mi J, et al. Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of miR-100-5p and miR-1246. Stem Cell Res Ther, 2022, 13:89.
doi: 10.1186/s13287-022-02764-9
|
|
|
[61] |
Wang B Y, Xu Y, Wei Y H, et al. Human mesenchymal stem cell-derived exosomal microRNA-143 promotes apoptosis and suppresses cell growth in pancreatic cancer via target gene regulation. Front Genet, 2021, 12:581694.
doi: 10.3389/fgene.2021.581694
|
|
|
[62] |
Zhang F, Lu Y Q, Wang M, et al. Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B. Molecular and Cellular Probes, 2020, 51: 101513.
doi: 10.1016/j.mcp.2020.101513
pmid: 31968218
|
|
|
[63] |
Kurniawati I, Liu M C, Hsieh C L, et al. Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic microRNA-let-7c delivery. Frontiers in Bioscience (Landmark Edition), 2022, 27(9): 256.
|
|
|
[64] |
Li C G, Sun Z, Song Y J, et al. Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer. Cancer Biology & Therapy, 2022, 23(1): 1-14.
|
|
|
[65] |
Huang L, Xiong J, Fu J, et al. Bone marrow mesenchymal stem cell-derived exosomal LINC00847 inhibits the proliferation, migration, and invasion of Ewing sarcoma. Journal of Clinical and Translational Research, 2022, 8:563-576.
pmid: 36518202
|
|
|
[66] |
Chen M J, Xia Z K, Deng J. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1α via a LMO4/HDAC2-dependent mechanism. Cell Biology and Toxicology, 2023, 39(4): 1319-1339.
doi: 10.1007/s10565-022-09759-5
|
|
|
[67] |
Mahjoor M, Afkhami H, Najafi M, et al. The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149(7): 3149-3160.
doi: 10.1007/s00432-022-04123-w
|
|
|
[68] |
Liu L, Cheng M X, Zhang T, et al. Mesenchymal stem cell-derived extracellular vesicles prevent glioma by blocking M2 polarization of macrophages through a miR-744-5p/TGFB1-dependent mechanism. Cell Biology and Toxicology, 2022, 38(4): 649-665.
doi: 10.1007/s10565-021-09652-7
pmid: 34978010
|
|
|
[69] |
Li N, Wang B M.Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression. Cell Death Discovery, 2022, 8: 205.
doi: 10.1038/s41420-022-00932-7
pmid: 35428780
|
|
|
[70] |
Gao G, Wang L Q, Li C F. Circ_0006790 carried by bone marrow mesenchymal stem cell-derived exosomes regulates S100A11 DNA methylation through binding to CBX7 in pancreatic ductal adenocarcinoma. Am J Cancer Res, 2022, 12:1934-1959.
pmid: 35693076
|
|
|
[71] |
Lou G H, Chen L, Xia C X, et al. miR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. Journal of Experimental & Clinical Cancer Research: CR, 2020, 39(1): 4.
|
|
|
[72] |
Jiang D, Wu X, Sun X Y, et al. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11. J Nanobiotechnology, 2022, 20:29.
doi: 10.1186/s12951-021-01206-7
|
|
|
[73] |
Hu Y, Liu H Y, Xiao X D, et al. Bone marrow mesenchymal stem cell-derived exosomes inhibit triple-negative breast cancer cell stemness and metastasis via an ALKBH5-dependent mechanism. Cancers, 2022, 14(24): 6059.
doi: 10.3390/cancers14246059
|
|
|
[74] |
Zhou W X, Zhou Y, Chen X L, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials, 2021, 268: 120546.
doi: 10.1016/j.biomaterials.2020.120546
|
|
|
[75] |
Abas B I, Demirbolat G M, Cevik O. Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS One, 2022, 17(9): e0274607.
doi: 10.1371/journal.pone.0274607
|
|
|
[76] |
Chen M Z, Li Y Y, Ma N F, et al. Mesenchymal stem cell-derived exosomes loaded with 5-Fu against cholangiocarcinoma in vitro. Molecular Medicine Reports, 2022, 25(6): 213.
doi: 10.3892/mmr
|
|
|
[77] |
Wei H X, Chen F, Chen J Y, et al. Mesenchymal stem cell derived exosomes as nanodrug carrier of doxorubicin for targeted osteosarcoma therapy via SDF1-CXCR4 axis. International Journal of Nanomedicine, 2022, 17: 3483-3495.
doi: 10.2147/IJN.S372851
pmid: 35959282
|
|
|
[78] |
He X M, Hong W Q, Yang J Y, et al. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduction and Targeted Therapy, 2021, 6(1): 1-14.
doi: 10.1038/s41392-020-00451-w
|
|
|
[79] |
Pang S H M, D’Rozario J, Mendonca S, et al. Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nature Communications, 2021, 12(1): 1-19.
doi: 10.1038/s41467-020-20314-w
|
|
|
[80] |
Wang J, Cao Z Y, Wang P P, et al. Apoptotic extracellular vesicles ameliorate multiple myeloma by restoring fas-mediated apoptosis. ACS Nano, 2021, 15(9): 14360-14372.
doi: 10.1021/acsnano.1c03517
pmid: 34506129
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|